ESTIMATED
04/30/2024
04/30/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | $0.80 | $0.80 | $0.80 |
Q2 2024 | 11 | $0.90 | $1.19 | $1.08 |
Q3 2024 | 5 | $1.16 | $1.16 | $1.16 |
Q4 2024 | 8 | $1.27 | $1.27 | $1.27 |
Q1 2025 | 5 | $0.99 | $0.99 | $0.99 |
Q2 2025 | 5 | $1.36 | $1.36 | $1.36 |
Q3 2025 | 7 | $1.39 | $1.39 | $1.39 |
Q4 2025 | 10 | $1.41 | $1.41 | $1.41 |
Q1 2026 | 4 | $1.13 | $1.13 | $1.13 |
Q2 2026 | 4 | $1.50 | $1.50 | $1.50 |
Q3 2026 | 7 | $1.56 | $1.56 | $1.56 |
Q4 2026 | 4 | $1.61 | $1.61 | $1.61 |
Incyte Corporation last posted its earnings results on Tuesday, April 30th, 2024. The company reported $0.64 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by $0.2. The company had revenue of 880.89 M for the quarter and had revenue of 3.70 B for the year. Incyte Corporation has generated $3 earnings per share over the last year ($2.65 diluted earnings per share) and currently has a price-to-earnings ratio of 17.26. Incyte Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 30th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/30/2024 | Q1 2024 | $0.84 | $0.76 | -0.08 | $921.89 M | $880.89 M | 02/16/2024 | Q4 2023 | $0.90 | $1.00 B | $1.01 B | 10/31/2023 | Q3 2023 | $1.09 | $0.76 | -0.33 | $919.03 M | 08/01/2023 | Q2 2023 | $0.83 | $0.91 | 0.08 | $954.61 M | 05/02/2023 | Q1 2023 | $0.85 | $0.10 | -0.75 | $859.17 M | $808.67 M | 02/07/2023 | Q4 2022 | $0.59 | $0.13 | -0.46 | $878.25 M | $926.70 M | 11/01/2022 | Q3 2022 | $0.72 | $0.51 | -0.21 | $823.30 M | 08/02/2022 | Q2 2022 | $0.79 | $0.73 | -0.06 | $911.40 M | 05/03/2022 | Q1 2022 | $0.57 | $0.17 | -0.4 | $733.24 M | 02/08/2022 | Q4 2021 | $0.84 | $2.55 | 1.71 | $812.44 M | $862.85 M | 11/02/2021 | Q3 2021 | $0.76 | $0.82 | 0.06 | $746.09 M | $812.99 M | 08/03/2021 | Q2 2021 | $0.74 | $0.68 | -0.06 | $685.41 M | $705.71 M | 05/04/2021 | Q1 2021 | $0.65 | $0.24 | -0.41 | $604.72 M | 02/09/2021 | Q4 2020 | $0.82 | $0.68 | -0.14 | $660.12 M | $789.51 M | 11/05/2020 | Q3 2020 | $0.72 | -$0.07 | -0.79 | $622.63 M | $620.64 M | 08/04/2020 | Q2 2020 | $0.87 | $1.33 | 0.46 | $608.32 M | $688.04 M | 05/05/2020 | Q1 2020 | $0.08 | -$3.33 | -3.41 | $568.51 M | 02/13/2020 | Q4 2019 | $0.57 | $0.51 | -0.06 | $575.04 M | $579.39 M | 10/29/2019 | Q3 2019 | $0.65 | $0.60 | -0.05 | $534.94 M | $551.58 M | 07/30/2019 | Q2 2019 | $0.49 | $0.49 | 0 | $497.81 M | $529.93 M |
---|
A. Incyte Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 30th, 2024 based off last year's report dates.
A. The conference call for Incyte Corporation's latest earnings report can be listened to online.
A. The conference call transcript for Incyte Corporation's latest earnings report can be read online.
A. Incyte Corporation (NASDAQ:INCY) has a recorded annual revenue of $3.70 B.
A. Incyte Corporation (NASDAQ:INCY) has a recorded net income of $3.70 B. Incyte Corporation has generated $2.67 earnings per share over the last four quarters.
A. Incyte Corporation (NASDAQ:INCY) has a price-to-earnings ratio of 17.26 and price/earnings-to-growth ratio is 1.19.